Full Text
EE493 Cost Effectiveness of Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in China

Abstract

Authors

Hanrui Zheng Linke Zou Ming Hu

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×